USE OF PDE5 INHIBITORS IN THE TREATMENT OF SCARRING AND FIBROSIS

This invention relates to the use of selective cyclic guanosine 3', 5'-monophosphate type five (cGMP PDE5} inhibitors (hereinafter PDE5 inhibitors), including in particular the compound sildenafil, for the treatment of or prevention of scarring or fibrosis in tissue. L'invention conce...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	BUTT, RICHARD, PHILIP, PHILLIPS, STEPHEN, CHARLES
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This invention relates to the use of selective cyclic guanosine 3', 5'-monophosphate type five (cGMP PDE5} inhibitors (hereinafter PDE5 inhibitors), including in particular the compound sildenafil, for the treatment of or prevention of scarring or fibrosis in tissue. L'invention concerne l'utilisation d'inhibiteurs sélectifs de la guanosine 3', 5'-monophosphate cyclique du type cinq (cGMP PDE5} (ci-après dénommés inhibiteurs de PDE5), comprenant notamment le composé sildénafil, pour le traitement ou la prévention de la formation de cicatrices et de la fibrose au niveau du tissu.